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S-adenosylmethionine (AdoMet) is an essential compound in cellular transmethylation reactions
and a precursor of polyamine and glutathione synthesis in the liver. In liver injury, the synthesis
of AdoMet is impaired and its availability limited. AdoMet administration attenuates experimen-
tal liver damage, improves survival of alcoholic patients with cirrhosis, and prevents experimental
hepatocarcinogenesis. Apoptosis contributes to different liver injuries, many of which are pro-
tected by AdoMet. The mechanism of AdoMet’s hepatoprotective and chemopreventive effects
are largely unknown. The effect of AdoMet on okadaic acid (OA)-induced apoptosis was evalu-
ated using primary cultures of rat hepatocytes and human hepatoma cell lines. AdoMet protected
rat hepatocytes from OA-induced apoptosis dose dependently. It attenuated mitochondrial cy-
tochrome c release, caspase 3 activation, and poly(ADP-ribose) polymerase cleavage. These ef-
fects were independent from AdoMet-dependent glutathione synthesis, and mimicked by 5*-
methylthioadenosine (MTA), which is derived from AdoMet. Interestingly, AdoMet and MTA
did not protect HuH7 cells from OA-induced apoptosis; conversely both compounds behaved as
proapoptotic agents. AdoMet’s proapoptotic effect was dose dependent and observed also in
HepG2 cells. In conclusion, AdoMet exerts opposing effects on apoptosis in normal versus
transformed hepatocytes that could be mediated through its conversion to MTA. These effects
may participate in the hepatoprotective and chemopreventive properties of this safe and well-
tolerated drug. (HEPATOLOGY 2002;35:274-280.)
S-adenosylmethionine (AdoMet) is the first product of methi-onine metabolism in mammals.1,2 Although present in alltissues, AdoMet is mainly synthesized and consumed in the
liver, where it serves as a methyl donor in numerous metabolic
reactions and a precursor for glutathione (GSH) and poly-
amines.1,2 In the biosynthesis of polyamines, 59-methylthioad-
enosine (MTA) is generated as an end-product.3 AdoMet synthesis
is impaired in experimental models of liver injury and patients with
alcohol-induced or viral cirrhosis (reviewed in Mato et al.2).
AdoMet administration protects against liver damage elicited by a
number of hepatotoxins, including ethanol, CCl4, galactosamine,
acetaminophen, bile acids, or the administration of a choline-de-
ficient diet.2,4-6 Furthermore, the administration of AdoMet to
patients with alcohol-induced cirrhosis improves survival or delays
liver trasplantation.7 Chemoprevention of liver carcinogenesis in-
duced by a variety of hepatocarcinogens is another remarkable
effect of AdoMet.8 The molecular mechanism(s) of the hepatopro-
tective and chemopreventive actions of AdoMet is not completely
known. Restoration of depleted GSH levels in the hepatocyte has
been proposed to play a role in AdoMet’s hepatoprotective action.2
Interestingly, some of the beneficial effects of AdoMet on liver
function, including protection from oxidative injury, prevention
of liver fibrosis, inhibition of growth of preneoplastic lesions and
hepatocyte proliferation, are mimicked by MTA, which is not a
GSH precursor nor a methylating agent.9-12
The role of apoptosis in liver cell injury is a topic of active
research.13,14 Death by apoptosis occurs in many of the above-
mentioned experimental liver injuries and in different human liver
diseases in which AdoMet grants protection.6,13,14 To better un-
derstand AdoMet’s mechanism(s) of hepatoprotection and chemo-
prevention, we examined its effect on okadaic acid (OA)-induced
apoptosis15 in normal versus transformed hepatocytes.
Abbreviations: AdoMet, S-adenosyl-L-methionine; GSH, glutathione; MTA, 59-
methylthioadenosine; OA, okadaic acid; PPG, propargylglycine; PARP, poly(ADP-ri-
bose) polymerase; EF, enrichment factor.
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Materials. AdoMet, in the stable form of sulfate-p-toluensul-
fonate salt, and 59-deoxy-59-methyl-thioadenosine (MTA) were
from Knoll Farmaceutici (Milan, Italy). D-L-Propargylglycine
(PPG) was from Sigma (St. Louis, MO). OA, the caspase 3 inhib-
itor Ac-DEVD-CHO, and anti-actin antibody were from Calbio-
chem (La Jolla, CA). Cell culture reagents were from Gibco BRL
(Grand Island, NY). Poly(ADP-ribose)polymerase (PARP) poly-
clonal antibody was from Santa Cruz Biotechnologies (Santa Cruz,
CA). Cytochrome c monoclonal antibody was from Pharmingen
(San Diego, CA). Other reagents were from Sigma.
Isolation, Culture, and Treatment of Rat Hepatocytes and
Human Liver Cancer Cells. Hepatocytes were isolated from
male Wistar rats (200-250 g) by collagenase perfusion and cultured
as previously described.16 All animals received humane care in
compliance with the National Research Council’s criteria for hu-
mane care as outlined in the “Guide for the Care and Use of
Laboratory Animals” prepared by the National Academy of Sci-
ences and published by the National Institute of Health (NIH
publication no 86-23, revised 1985).
AdoMet or MTA (dissolved in dimethyl sulfoxide; final concen-
trations of dimethyl sulfoxide never exceeded 0.1%) was added to
culture medium 30 minutes prior to the addition of 20 nmol/L
OA. Experiments were performed in minimal essential medium
containing 1% fetal bovine serum. PPG was added at a concentra-
tion of 2 mmol/L 30 minutes prior to the addition of AdoMet.
Where indicated, the caspase 3 inhibitor Ac-DEVD-CHO (0.1
mmol/L) was added 3 hours before OA addition. HuH7 cells were
cultured in Dulbecco’s modified Eagle’s medium supplemented
with 5% fetal bovine serum, glutamine, and antibiotics. They were
treated with OA (125 nmol/L) in the presence or absence of
AdoMet or MTA. In separate experiments, HuH7 and HepG2
cells were cultured using Dulbecco’s modified Eagle’s medium
containing 10% fetal bovine serum, antibiotics, and glutamine.
Cells were plated at a density of 5 3 105 cells per 35-mm well,
treated with varying concentrations of AdoMet (0 to 1 mmol/L)
for 24 hours, and processed for detection of apoptotic cells using
flow cytometry (see below).
Determination of Oligonucleosomal (Histone-Associated)
DNA Fragments. The presence of soluble histone-DNA com-
plexes was measured by the Cell Death Detection Assay (Boehr-
inger Mannheim, Mannheim, Germany). Cell death enzyme-
linked immunosorbent assays were performed according to the
manufacturer’s instructions. Specific enrichment of mono- and
oligonucleosomes released into the cytoplasm (enrichment factor,
EF) was calculated as the ratio between the absorbance values of the
samples obtained from treated and control cells.
Flow Cytometry. After treatment with AdoMet or vehicle,
HuH7 and HepG2 cells (106) were trypsinized and collected by
centrifugation at 1,000g for 5 minutes. Cells were washed in phos-
phate-buffered saline, resuspended, and fixed in 70% ethanol for at
least 2 hours. Next, cells were centrifuged at 200g for 5 minutes,
washed in phosphate-buffered saline, resuspended in 500 mL phos-
phate-buffered saline containing 100 mg RNase, and incubated for
30 minutes at 37°C on a shaker. Cellular DNA was then stained by
the addition of 10 mg propidium iodide, and a total of 10,000
cells/condition were analyzed on a FACScan utilizing Cellquest
software (Becton Dickinson, Franklin Lakes, NJ).
Measurement of Intracellular GSH Levels. Intracellular
GSH levels (reduced form) were determined as previously de-
scribed.16
Western Blot Analysis. Western blot analysis was performed
as previously described.16 PARP was analyzed in whole cell lysates
and cytochrome c in cytosolic fractions obtained by differential
centrifugation in 250 mmol/L sucrose buffer as described else-
where.17
Measurement of Caspase 3 Activity. Caspase 3 activity was
measured in rat hepatocytes treated for 4 hours with OA (20
nmol/L) in the presence or absence of AdoMet or MTA, using the
Caspase-3/CPP32 Colorimetric Assay Kit (BioVision, Palo Alto,
CA). Cells (3 3 106) were scraped in culture medium, pelleted,
and resuspended in lysis buffer and caspase 3 activity was measured
following the manufacturer’s instructions.
Statistical Analysis. The data were analyzed using the
Kruskal-Wallis test to determine differences between all indepen-
dent groups. When significant differences were obtained (P ,
.05), differences between 2 groups were tested using the Mann-
Whitney U test.
Results
AdoMet Prevents OA-Induced Apoptosis of Rat Hepatocytes
in Primary Culture. OA is a potent and specific inhibitor of
protein phosphatases that induces apoptosis in several cell types,
including rat hepatocytes.15,18,19 The antiapoptotic potential of
AdoMet was evaluated in hepatocytes treated with 20 nmol/L OA
for 8 hours. Apoptosis was assessed by the presence of oligonucleo-
somal fragments in the cytoplasm of the cells, which reflects the
extent of DNA fragmentation and nuclear disruption characteris-
tic of apoptosis.13 AdoMet dose dependently prevented the forma-
tion of oligonucleosomal fragments induced by OA (Fig. 1). The
protective effect of AdoMet was also observed after 24 hours of
treatment with OA (data not shown). These results always corre-
lated with cell survival measured by MTT assay in hepatocytes
(data not shown). The inactive structural analog norokadaone ex-
erted no apoptotic effect indicating that, as reported,20 inhibition
of phosphatase(s) activity by OA is responsible for the induction of
cell death.
The Antiapoptotic Action of AdoMet is GSH Independent
and Mimicked by MTA. One of the AdoMet’s mechanisms of
hepatoprotection may be its ability to serve as a precursor for GSH
synthesis.1,2 In this regard, AdoMet prevented tumor necrosis fac-
tor-a–induced necrotic cell death in hepatocytes from ethanol-fed
rats through the restoration of depleted mitochondrial GSH lev-
els.21 To evaluate whether AdoMet exerted its antiapoptotic effect
on OA-induced apoptosis through GSH synthesis, we determined
the intracellular levels of GSH in hepatocytes treated with OA. OA
significantly increased total cellular GSH levels (from control
19.3 6 6.2 to 44.3 6 4.1 nmol/106 cells in OA-treated hepato-
cytes, P , .05), ruling out the possibility of GSH depletion as a
mechanism for apoptosis. This increase could be attributed to
induction by OA of g-glutamylcysteine synthetase expression,
the rate-limiting enzyme for GSH synthesis.22 The role of GSH
was further analyzed in experiments using PPG, an inhibitor of
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g-cystathionase,23 which is an effective way of blocking GSH syn-
thesis from AdoMet. As shown in Fig. 2A, the protective action of
AdoMet in OA-induced apoptosis was not affected by 2 mmol/L
PPG. Under these conditions we observe effective inhibition in
GSH synthesis in AdoMet-treated hepatocytes (13.25 6 1.2
nmol/106 cells in controls, 2.58 6 0.6 nmol/106 cells in PPG-
treated cultures, 20.1 6 2.9 nmol/106 in AdoMet-treated cells and
2.46 6 0.7 nmol/106 cells in PPG plus AdoMet-treated cultures)
and cystathionine accumulation (6.45 6 0.77 and 10.22 6 1.43
nmol/mg of protein in PPG-treated vs. PPG plus AdoMet-treated
hepatocytes, respectively, P , .05). In the absence of PPG cysta-
thionine was not detectable.
As mentioned above, some of the effects of AdoMet on liver
damage and neoplastic transformation are mimicked by MTA.
This compound is derived from AdoMet metabolism in the poly-
amine biosynthetic pathway, and can also arise from nonenzymatic
hydrolysis of AdoMet under physiologic conditions.24 Hence, we
evaluated the effect of MTA on OA-induced apoptosis. Pretreat-
ment of hepatocytes with MTA abolished the apoptotic effect of
OA (Fig. 2B). The protective effect of MTA was dose dependent,
but occurred at much lower concentrations than AdoMet.
AdoMet and MTA Attenuate Cytochrome c Release,
Caspase 3 Activation, and PARP Degradation Induced by OA.
Apoptosis induced by OA in primary rat hepatocytes is mediated
by the release of cytochrome c from the mitochondria and the
subsequent activation of caspase 3.25 The effect of AdoMet and
MTA on these two biochemical parameters was studied. As shown
in Fig. 3A, both AdoMet and MTA effectively inhibited the release
of cytochrome c induced by OA. Once released into the cytosol,
cytochrome c can contribute to the activation of caspase 3.13
Caspase 3 activity was induced about 3-fold in OA-treated cells as
compared with untreated controls. When hepatocytes were pre-
treated with AdoMet or MTA, there was a dose-dependent inhi-
bition of caspase 3 activity (Fig. 3B).
PARP is a well-characterized substrate for effector caspases, such
as caspase 3.26 Although caspase activation by several apoptotic
stimuli did not result in proteolysis of PARP in hepatocytes,27 OA
was shown to induce it.25 OA-induced PARP proteolysis was
shown by the disappearance of the 116-kd intact PARP protein
and the appearance of an 85-kd proteolytic fragment, both of
which are recognized by the same antibody. PARP proteolysis was
attenuated in cells pretreated with AdoMet and almost completely
prevented by MTA (Fig. 3C).
Effect of AdoMet and MTA on OA-Induced Apoptosis in
HuH7 Cells. AdoMet and MTA prevented the development of
liver tumors in different experimental models of hepatocarcino-
genesis in vivo,8,10 and this was associated with the appearance of
apoptotic bodies in hepatic nodules.28 Because AdoMet and MTA
are antiapoptotic in primary hepatocytes, we determined their ef-
fects in HuH7 cells. It is known that OA induces apoptosis in
HuH7 cells, although at higher doses than that required for pri-
mary hepatocytes (up to 500 nmol/L).20 Apoptosis in HuH7 cells
Fig. 2. AdoMet’s antiapoptotic effect is not mediated through AdoMet-
dependent GSH synthesis and is mimicked by MTA in cultured rat hepato-
cytes. (A) The g-cystathionase inhibitor PPG (2 mmol/L) was added to all
plates 30 minutes before the onset of treatments. Apoptosis was induced by
OA (20 nmol/L, 8 hours) in the presence or absence of AdoMet (4 mmol/L).
AdoMet provided protection from apoptosis in the absence of AdoMet-
dependent GSH synthesis. (B) Increasing concentrations of MTA were added
to cultured rat hepatocytes 30 minutes before the addition of OA (20
nmol/L), and cells were tretated for 8 hours. In both cases (A and B)
apoptosis, assessed by measuring specific enrichment of mono- and oligo-
nucleosomes released into the cytoplasm (EF), was calculated as the ratio
between the absorbance values obtained in control (C) and treated samples.
Data are means 6 SEM of 3 independent experiments performed in
triplicate. *P , .01 vs. control; **P , .05 vs. OA-treated hepatocytes;
***P , .01 vs. OA-treated hepatocytes.
Fig. 1. AdoMet protects cultured rat hepatocytes from OA-induced apo-
ptosis. Hepatocytes were treated with OA (20 nmol/L) for 8 hours in the
presence of increasing concentrations of AdoMet. Apoptosis, assessed by
measuring specific enrichment of mono- and oligonucleosomes released into
the cytoplasm (EF), was calculated as the ratio between the absorbance
values obtained in control (C) and treated samples. Norokadaone (NOR, 20
nmol/L), an inactive structural analog of OA, was used as a control. Results
are means 6 SEM of 3 independent experiments performed in triplicate.
*P , .01 vs. control; **P , .05 vs. OA-treated hepatocytes; ***P , .01
vs. OA-treated hepatocytes.
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was measured after 24 hours of treatment with 125 nmol/L OA. In
some cultures, 4 mmol/L AdoMet or 500 mmol/L MTA was added
prior to OA. As shown in Fig. 4A, neither AdoMet nor MTA
prevented the accumulation of cytoplasmic oligonucleosomal frag-
ments induced by OA. Moreover, treatment with AdoMet or
MTA alone resulted in a proapoptotic effect similar to that ob-
served with OA (Fig. 4A). Neither AdoMet nor MTA potentiated
the effect of OA (Fig. 4A). The effect of AdoMet and MTA on
cytochrome c release to the cytosol in HuH7 cells was also studied.
As shown in Fig. 4B, treatment of HuH7 cells with 4 mmol/L
AdoMet or 500 mmol/L MTA for 8 hours resulted in the release of
cytochrome c into the cytosolic fraction. As expected, this effect
was also observed in response to OA treatment (125 nmol/L, 8
hours) (Fig. 4B), and was not potentiated when cells were simul-
taneously treated with either AdoMet or MTA (Fig. 4B). We next
determined whether AdoMet’s proapoptotic effect was unique to
HuH7 cells. In these experiments, HuH7 and HepG2 cells were
treated with varying concentrations of AdoMet for 24 hours and
the percent of apoptotic cells was determined by flow cytometry.
As shown in Fig. 4C, AdoMet exerted a dose-dependent increase in
the percent of apoptotic cells in both cell lines.
Discussion
There is accumulating evidence on the protective potential of
AdoMet in the preservation of liver function, both in a variety of
experimental models of liver damage and in human alcohol-in-
duced liver disease.2,4-9,11 As mentioned above, cell death by apo-
ptosis is becoming a relevant process in the development of liver
injury under different pathologic conditions that are palliated by
AdoMet treatment. Hence, it was interesting to directly address
the effect of AdoMet on apoptosis. For this purpose we have used
an experimental model of rat hepatocytes in primary culture in
which apoptosis was induced by OA. OA has been previously
shown to induce apoptosis in primary cultured rodent hepatocytes
and hepatic-derived cell lines.15,20,25 As opposed to other proapop-
totic stimuli, such as tumor necrosis factor-a and Fas ligand,13,27
OA-mediated apoptosis of cultured hepatic cells does not need a
cotreatment with inhibitors of messenger RNA or protein synthe-
sis.15,20,25 In this experimental setting we have observed that
AdoMet partially prevented apoptotic cell death induced by OA in
a dose-dependent fashion. AdoMet effect was accompanied by the
inhibition of cytochrome c release from mitochondria to the cy-
tosol. This is a central event in the apoptotic pathway, and a com-
mon response to different apoptosis-inducing agents.29 Cyto-
chrome c release leads to the activation of downstream effector
caspases, such as caspase 3, which cleaves a number of cellular
proteins facilitating DNA fragmentation and cell death.13,30 Con-
sistent with this, AdoMet treatment partially protected against
OA-induced caspase 3 activation and PARP cleavage. PARP is a
substrate of caspase 3, which recognizes the DEVD motif in PARP
and processes this protein to the 85-kd form.31,32 PARP cleavage
was not observed in hepatocytes undergoing death-receptor–me-
diated apoptosis in reponse to agonists such as tranforming growth
factor b or Fas ligand.27,33 However, we observed that hepatocyte
Fig. 3. AdoMet and MTA attenuate OA-induced mitochondrial cytochrome c release, caspase 3 activation and PARP cleavage. (A) Western blot analysis
of cytochrome c levels in the cytoplasm of control hepatocytes (C), OA-treated hepatocytes (20 nmol/L), and hepatocytes treated with AdoMet (4 mmol/L)
or MTA (500 mmol/L) in the presence or absence of OA for 8 hours. Blots were probed for b-actin as loading control. This experiment was performed 3 times
with similar results, and a representative blot is shown. (B) Inhibition of OA-induced caspase 3 activity in cultured rat hepatocytes treated with OA (20 nmol/L)
for 4 hours in the presence of different concentrations of AdoMet or MTA. Data are means 6 SEM of 3 independent experiments performed in triplicate. *P ,
.05 vs. control cells; **P , .05 vs. hepatocytes treated with OA alone. (C) Western blot analysis of PARP (116 kd) and its proteolytic fragment (85 kd) in
control cells (C) and hepatocytes treated with OA (20 nmol/L) for 8 hours in the absence or presence of AdoMet (4 mmol/L), MTA (500 mmol/L) or the
caspase 3 inhibitor Ac-DEVD-CHO (0.1 mmol/L). This experiment was performed 3 times with similar results, and a representative blot is shown.
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apoptosis induced by OA is accompanied by PARP proteolysis,
which is consistent with other reports.25 Similar to AdoMet, pre-
vention of these events by ursodeoxycholic acid was associated with
protection from apoptosis.15,25
The biochemical mechanisms underlying the hepatoprotective
effects of AdoMet are not completely known. Facilitation of meth-
ylation reactions and the restoration of depleted hepatocellular
GSH levels, among other effects, have been proposed4-6,34 (re-
viewed in Mato et al.2). AdoMet addition to isolated hepatocytes
restores intracellular AdoMet concentrations and increases GSH
levels.11,35 We examined whether AdoMet protection from OA-
induced apoptosis could depend on AdoMet-dependent GSH syn-
thesis. For this purpose hepatocytes were treated with AdoMet in
the presence or absence of PPG, an inhibitor of g-cystathionase,
the enzyme that converts AdoMet-derived cystathionine into the
GSH precursor cysteine.1,23 Under these conditions AdoMet re-
tained its antiapoptotic properties when cells were challenged with
OA, thus ruling out the possible implication of GSH in this effect
of AdoMet.
As previously mentioned, MTA is a product of AdoMet metab-
olism in the polyamine pathway.1 Exogenous AdoMet can also
undergo nonenzymatic hydrolysis in vivo into MTA and homo-
serine.9,24 It has been suggested that the beneficial effects of
AdoMet in liver damage could be attributed in part to its conver-
sion to MTA.9,10 Additionally, we have recently shown that MTA
mimics AdoMet’s effect on gene expression in cultured rat hepa-
tocytes.12 Now we observe that MTA also prevents OA-induced
apoptosis in cultured rat hepatocytes in a dose-dependent fashion.
Inhibition of apoptosis by MTA was accompanied by the preven-
tion of cytochrome c release from the mitochondria, caspase 3
activation, and PARP cleavage. In contrast to AdoMet, MTA does
not contribute to GSH synthesis, is not a methyl donor, and in-
hibits methyltransferases.36 These observations further support the
idea that the present antiapoptotic effects of AdoMet are GSH
independent and suggest that they could be mediated in part
through its conversion to MTA.
A possible mechanism for the antiapoptotic effect of AdoMet
could take place at the mitochondrial level. AdoMet is transported
into isolated rat liver mitochondria via a specific carrier-mediated
system, thus making this organelle an intracellular target for
AdoMet.37 Apoptotic signals, including OA, alter mitochondrial
physiology leading to organelle swelling and the physical rupture of
the outer membrane.14,25,30 These alterations contribute to the
release of mitochondrial proteins, such as cytochrome c and other
death-promoting proteins,30 into the cytosol. AdoMet has been
shown to restore the physical properties of mitochondria in etha-
Fig. 4. AdoMet or MTA treatment induces apoptosis in the human hepatocarcinoma cells HuH7 and HepG2. (A) HuH7 cells were treated with OA (125
nmol/L), AdoMet (4 mmol/L), MTA (500 mmol/L), or with OA plus AdoMet or MTA for 24 hours. Apoptosis, assessed by measuring specific enrichment of
mono- and oligonucleosomes released into the cytoplasm (EF), was calculated as the ratio between the absorbance values obtained in control (C) and treated
samples. Data are means 6 SEM of 3 independent experiments performed in triplicate. *P , .01 and **P , .05 vs. control values. (B) Western blot analysis
of cytochrome c levels in the cytoplasm of control HuH7 cells (C), OA-treated HuH7 cells (125 nmol/L) and HuH7 cells treated with AdoMet (4 mmol/L) or
MTA (500 mmol/L) in the presence or absence of OA for 8 hours. Blots were probed for b-actin as loading control. This experiment was performed 3 times
with similar results, and a representative blot is shown. (C) AdoMet dose-dependently induces apoptosis in both HuH7 and HepG2 cells. HuH7 and HepG2
cells were treated with AdoMet (0 to 1 mmol/L) for 24 hours. Apoptosis was assessed by flow cytometry as described in Materials and Methods. Data are
means 6 SEM of 4 independent experiments performed in triplicate. *P , .05 vs. control values.
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nol-fed rats,34 attenuate the increase in plasma of glutamate dehy-
drogenase, an enzyme exclusively located in the intermembrane
space of mitochondria, and decrease the number of giant mito-
chondria in chronically ethanol intoxicated baboons.4 Together
with our present observations, these findings suggest that AdoMet
can modulate mitochondrial injury. The inhibition of OA-in-
duced cytochrome c release by MTA also suggests that this com-
pound could mediate part of the above-mentioned effects of
AdoMet at the mitochondrial level. Interestingly, higher concen-
trations of AdoMet were necessary to match the effects of MTA in
the different apoptosis-related events measured. This could be at-
tributed in part to the differential intracellular availability of both
compounds, AdoMet being a charged molecule and MTA a non-
charged compound. Additionally, and as suggested by our present
experiments, AdoMet effects may depend on the conversion of this
molecule, either spontaneous or via enzymatic catalysis, to MTA,
which would be bypassed by the direct addition of this compound.
While prevention of hepatocyte apoptosis under conditions of
liver injury contributes to the preservation of functional liver mass
and organ viability, such an effect would be undesired during the
clonal expansion of malignantly initiated hepatocytes. In this re-
spect, an imbalance between cell proliferation and apoptotic cell
death seems to be important in hepatocarcinogenesis, especially
during the stage of progression.38 These notions led us to test the
effect of AdoMet and MTA on apoptosis induced by OA in the
human hepatoma cell line HuH7. In contrast to the results ob-
tained in primary hepatocytes, AdoMet and MTA did not protect
from OA-induced apoptosis. On the contrary, both agents were
able to promote the release of cytochrome c from the mitochondria
into the cytoplasm and to induce apoptosis in the absence of any
other stimuli, mimicking the effect of OA. AdoMet’s proapoptotic
effect was also not unique to HuH7 cells, because it induced apo-
ptosis in both HepG2 and HuH7 cells in a dose-dependent man-
ner. Additionally, AdoMet and MTA also induced a similar pro-
apoptotic response in the rat hepatoma cell line H4-IIE (data not
shown), thus excluding the possibility that species differences
could be behind the differential effect of these two molecules be-
tween primary rat hepatocytes and human cell lines. This proapop-
totic effect of AdoMet on hepatoma cell lines is unrelated to
AdoMet-dependent GSH synthesis, given the fact that trans-
formed hepatocytes show a blockade in their ability to drive
AdoMet-derived homocysteine into the trans-sulfuration path-
way.39,40 These observations are in agreement with the reported
chemopreventive action of AdoMet in an in vivo model of chem-
ical hepatocarcinogenesis in rats, which was accompanied by an
increase of apoptotic bodies in nodules and foci in AdoMet-treated
animals.8,28 Now we show that this in vivo effect of AdoMet could
be partially mediated through a direct action of this molecule on
the neoplastic cell and suggest that AdoMet-derived MTA could be
a mediator of such an effect. Additionally, our present observations
are in line with our previously reported growth inhibitory proper-
ties of increased intracellular AdoMet levels on HuH7 cells.41 One
of the mechanisms of the growth inhibitory effect appears to be
apoptosis. How AdoMet/MTA can be antiapoptotic in primary
hepatocytes but proapoptotic in liver cancer cells is unknown and
is an area of our future investigation. However, this differential
effect seems not to be related to the fact that primary hepatocytes
are quiescent cells, whereas cell lines display enhanced prolifera-
tion, since AdoMet and MTA showed a similar antiapoptotic effect
on proliferating hepatocytes treated with hepatocyte growth factor
(data not shown).
Taken together, this work outlines a candidate novel role for
AdoMet in the preservation of liver cell viability that could be
behind the widely reported hepatoprotective actions of this mole-
cule. Its differential effects on normal and transformed hepatocytes
further strengthens the therapeutic potential of a safe and well-
tolerated drug in liver disease,7 and as a chemopreventive agent in
human hepatocarcinoma.
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